[Current data on radiochemotherapy and potential of targeted therapies for cervical cancers].
The present review represents an up-to-date focus on the particular topic of cervix carcinoma. An exhaustive description of the actual data and the near-future combination of radiotherapy and drugs with the specific potential of targeted therapies are presented. This approach represents one of the next challenges to improve results. Studies conducted in 1999, 2000, and 2002 reported the results of six large-scale prospective randomized trials using concomitant chemoradiation with a significant progression-free and overall survival rate improvement compared to radiotherapy only. These results were confirmed by the two last meta-analyses. Nowadays, the concurrent radiochemotherapy schedule used in the treatment of high risk cervical cancer is a standard practice. More growing evidences suggest that intracellular signal pathways play a significant role in radiation response. Several prognostic factors on tumoral radiosensitivity have been identified, including intracellular signal pathways, in the particular case of cervix carcinoma. Promising results have been obtained in experimental studies assessing the combined use of specific inhibitors and radiotherapy. Based on these data, a number of clinical trials have been started to enhance tumor responses and thus, to decrease the rate of recurrences.
Magné
N
N
Unité de Curiethérapie, Département de Radiothérapie, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, Villejuif, France.
Deutsch
E
E
Haie-Meder
C
C
D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D018714:Radiotherapy, Adjuvant; D015398:Signal Transduction; D002583:Uterine Cervical Neoplasms / Q000628:therapy*
D016328:NF-kappa B; D066246:ErbB Receptors